ACME LaboratoriesDHA:ACMELAB +0.37%82 ROE % is 10.10% as of Mar. 2026, which is 22% above its 10-year median of 8.25. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT124.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 933 Drug Manufacturers companies, ACME Laboratories ranks better than 54.02% on this metric.
The historical rank and industry rank for ACME Laboratories's ROE % or its related term are showing as below:
DHA:ACMELAB'
s ROE % Range Over the Past 10 Years
Min: 6.73 Med: 8.25 Max: 10.24
Current: 7.32
During the past 9 years, ACME Laboratories's highest ROE % was 10.24%. The lowest was 6.73%. And the median was 8.25%.
DHA:ACMELAB's ROE % is ranked better than 54.02% of 933
companies
in the Drug Manufacturers industry
Industry Median: 5.89
vs DHA:ACMELAB: 7.32
ACME Laboratories (DHA:ACMELAB) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
ACME Laboratories ROE % Related Terms
ACME Laboratories ROE % Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's ROE % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
ACME Laboratories (DHA:ACMELAB) has a ROE % of 10.10% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ACME Laboratories and its competitors. This is 22% above median its historical median of 8.25. Over the past decade, ACME Laboratories' ROE % has ranged from 6.73 to 10.24. According to the industry distribution chart, ACME Laboratories ranks #429 out of 933 companies in the Drug Manufacturers industry, placing it in the top 46%.
Is ACME Laboratories' ROE % too high?
ACME Laboratories' current ROE % of 10.10% is 22% above median its 10-year median of 8.25. Over the past 10 years, this metric has ranged from a low of 6.73 to a high of 10.24. The Drug Manufacturers industry median ROE % is 5.89. ACME Laboratories' value of 10.10% is 71.5% above this industry median. Based on the distribution chart, ACME Laboratories ranks #429 out of 933 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #429 out of 933 companies for ROE %. This puts ACME Laboratories in the upper half of its industry. The industry median ROE % is 5.89. ACME Laboratories' value of 10.10% is 71.5% above this benchmark. Historically, ACME Laboratories' own ROE % has ranged from 6.73 to 10.24 over the past decade. While the company's 10-year median is 8.25 vs. the industry median of 5.89, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.89, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current ROE % of 10.10% is 71.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current ROE % is 10.10%, which is 22% above median its own 10-year median of 8.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT124.74, compared to a current price of BDT81.30 — trading 34.8% below its estimated fair value. The current ROE % is 10.10%, which is 22% above median its 10-year median of 8.25 and 71.5% above the Drug Manufacturers industry median of 5.89. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current ROE % is 10.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT81.30 is trading 34.8% below its estimated GF Value™ of BDT124.74.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
ROE %: 10.10% (22% above median its 10-year median of 8.25)
GF Value™: BDT124.74 vs. price of BDT81.30 (34.8% below fair value)
Industry Position: 71.5% above the Drug Manufacturers median (#429 of 933)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
